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Messing et al. (2009) report the homodimeric structure of theBdellovibrio bacteriovorusRppH pyrophospho-
hydrolase, which hydrolyzes the mRNA 50 triphosphate to initiate bacterial mRNA decay. These structures
reveal insights into BdRppH substrate recognition and analogies to eukaryotic decapping enzymes.All cellular messenger RNAs (mRNAs)
possess distinct intrinsic half-lives and
are ultimately degraded. Cells have
evolved intricate strategies to stabilize
as well as to degrade their mRNAs
through defined pathways. In eukaryotes,
the 50 end of the mRNA is protected from
50 to 30 exonucleolytic activity by the pres-
ence of the 50 cap structure. In prokary-
otes, the 50 end of the newly transcribed
mRNA is not further modified and retains
the 50 triphosphate. Recent work indi-
cates that the 50 triphosphate in prokary-
otic mRNAs fulfills a protective function
similar to that of the cap structure in
eukaryotes (Celesnik et al., 2007). Identifi-
cation of RppH (ORF176/NudH/YgdP)
as a prokaryotic functional homolog of
a decapping enzyme that similarly re-
moves a diphosphate from the mRNA 50
end to generate a 50 monophosphate
mRNA (Deana et al., 2008) further reveals
the strategic conservation of mRNA
decay between prokaryotes and eukary-
otes (Figure 1).
RppH belongs to the Nudix superfamily
of enzymes that hydrolyze Nucleoside
diphosphates linked to other moiety X.
Members of the family, found in species
from bacteria to eukaryotes, share a highly
conserved 23 residues long Nudix signa-
ture motif, GX5EX7REUXEEXGU, where
U is a hydrophobic residue and X is anyresidue (McLennan, 2006). Messing et al.
(2009) resolved the structure of the pred-
atory bacterium Bdellovibrio bacteriovo-
rus RppH (BdRppH) protein in the apo
form and in complex with GTP. The struc-
ture reveals an asymmetric head-to-head
homodimer with a 20-residue interface
on each monomer mediated through
hydrophobic interactions and hydrogen
bonding. The co-crystal structure reveals
the GTP purine ring is arranged in a syn
conformation analogous to that observed
with the purine ring of the adenosine in
m7GpppA substrate complexed with the
Xenopus laevis X29 nuclear decapping
enzyme (Scarsdale et al., 2006), with
both purines positioned within a similar
cleft. The ring is stabilized by Phe52 and
Asn136, where Asn136 coordinates it in
a manner equivalent to Gln184 in X29.
The a- and g-phosphates of GTP are
further coordinated by BdRppH Arg40
and Lys56, respectively. Moreover, as
would be expected for an enzyme that
hydrolyzes the triphosphate moiety at
the 50 end of an mRNA, the 30 hydroxyl
of the guanosine appears unencumbered
and positioned toward the outer surface
of the protein, potentially providing an
exit site for a linked RNA molecule. Inter-
estingly, the authors state BdRppH lacks
an RNA binding structure referred to as
the Box B a-helix at the carboxyl terminusStructure 17, March 11, 200of the Nudix fold of X29, but propose that
a positive patch along helix a2 and a3
might serve this role. The overall similari-
ties in homodimer formation and
substrate binding suggest a mechanistic
conservation between BdRppH and X29
Nudix proteins in pyrophosphate hydro-
lysis.
All Nudix enzymes require divalent
cations for catalysis (McLennan, 2006).
The ions appear to be coordinated by
conserved residues in the Nudix motif. In
the case of BdRppH, Mg2+ is the
preferred cation. Each monomer of
BdRppH binds three Mg2+ ions coordi-
nated by residues Gly54, Glu70, Glu73,
and Glu74 and multiple water molecules.
In contrast, the prototypic prokaryotic
MutT Nudix protein requires two divalent
cations coordinated by a glycine and
four glutamates, including Glu53, which
functions as the general base (Mildvan
et al., 2005). Interestingly, unlike Glu53 in
MutT, substitution of the equivalent
residue in BdRppH, Glu70, has a modest
effect on kcat and is unlikely the catalytic
base, as it also directly coordinates two
cations. By extrapolation to the catalytic
base at structurally equivalent positions
within the GDPMH and ADPRase Nudix
proteins (Mildvan et al., 2005), the direct
involvement of two histidines within loop
L6 as potential residues responsible for9 ª2009 Elsevier Ltd All rights reserved 317
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Previewsthe catalytic hydrolysis step
of BdRppH were tested.
However, single and double
mutants of His115 and
His116 ruled out a role for
these histidines as the
general base for the BdRppH
catalytic step as well. The
authors propose that flexi-
bility of the L6 loop may
enable alternative residues
or a solvent hydroxyl to fulfill
the catalytic function. Further
mutagenesis studies are
needed to precisely delimit
the residues involved in the
catalysis step.
Unlike the cytoplasmic
Dcp2 mRNA decapping
protein that only functions
on a cap structure linked to
an RNA moiety and lacks
hydrolytic activity on a nucle-
otide substrate (Wang et al.,
2002), BdRppH contains
a broader substrate speci-
ficity and can function as
a dGTPase (Steyert et al.,
2008), in addition to its
mRNA 50 triphosphate pyro-
phosphohydrolase activity.
BdRppH dual substrate
hydrolytic activity is not
restricted to in vitro reactions
because it can complement
the dGTPase deficiency in
DmutT E. coli (Steyert et al.,
2008) as well as mRNA pyro-
phosphohydrolase activity to
restore mRNA decay in
DrppH E. coli (Deana et al.,
2008). Why E. coli have taken
a specialization route to
utilize two proteins, MutT
and RppH for the dGTPase
and mRNA pyrophosphohy-
drolase activities respec-
tively, while both functions
can be carried out by BdRppH in B. bac-
teriovorus is not apparent. Nor are the
potential modulatory pathways that might
exist to shunt BdRppH into a dGTPase or
an mRNA pyrophosphohydrolase in cells.
Remarkably, an additional wrinkle was
recently added to the pyrophosphohydro-
lase class of enzymes. Xiang et al. (2009)
reported that removal of a pyrophosphate
from an mRNA 50 triphosphate is not
restricted to bacteria, nor is it restricted
to Nudix proteins. Despite the lack of
a discernable nuclease domain, crystal
structures of the yeast Rat1 interacting
protein, Rai1, and the mouse DOM3Z
homolog revealed a potential octahedral
catalytic pocket capable of coordinating
a metal ion. Biochemical studies
confirmed a catalytic activity for Rai1
and interestingly demonstrated that it
can hydrolyze the triphosphate group at
the 50 end of an mRNA to remove a pyro-
phosphate and generate a 50
monophosphorylated mRNA,
a function analogous to
RppH and BdRppH. The
functional significance of
Rai1 pyrophosphohydrolase
activity in eukaryotes where
mRNAs are capped at the 50
end is unclear, although
a role in 50 end quality control
was proposed by the authors.
These finding further highlight
the functional similarities that
exist between prokaryotic
and eukaryotic mRNA decay
mechanisms and emphasizes
our current rudimentary
understanding of the com-
plexity of nucleases involved
in mRNA decay.
The BdRppH crystal struc-
ture represents the first
example of a bacterial Nudix
pyrophosphohydrolase and
provides important clues into
its molecular mechanism and
potential avenues for struc-
ture-based therapeutic anti-
bacterial approaches. These
studies raise interesting
avenues for future studies,
including how does BdRppH
accommodate and hydrolyze
more than one substrate while
the corresponding mamma-
lian decapping enzymes only
function on capped mRNA?
Are additional proteins
involved in regulating these
distinct pyrophosphohydro-
lase activities in bacteria? For
example, are there 50 end
triphosphate binding proteins
in prokaryotes analogous to
the eIF4E cap binding protein
in eukaryotes to protect the 50
end? Do prokaryotes contain
additional proteins that hydro-
lyze mRNA 50 triphosphate? As our long-
held belief that prokaryotic and eukaryotic
mRNA decay pathways are distinct begins
to crumble, it is becoming more apparent
that distant but analogous mechanisms
have converged evolutionarily.
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Figure 1. Analogies between Prokaryotic and Eukaryotic mRNA
Decay
The paradigm that the endonucleolytic activity of RNase E initiates mRNA
decay in E. coli was changed with the discovery of the RppH pyrophosphohy-
drolase (Celesnik et al., 2007; Deana et al., 2008). RppH removes a protective
diphosphate at the 50 end of a triphosphorylated mRNA to generate a 50 mono-
phosphorylated mRNA. RNase E has a higher affinity for an mRNA 50 mono-
phosphate to facilitate endonucleolytic cleavage of the mRNA (Condon,
2007). The fragments are degraded by 30 to 50 exonucleases, including
PNPase. Decay of fragments bearing secondary structures may also be
enhanced by an initial polyadenylation, which provides a toehold for nucle-
ases. A 50 monophosphorylated mRNA could also be a substrate for the 50
to 30 exoribonuclease RNase J1 in Bacillus subtilis (Condon, 2007). The asso-
ciation of either protein with the 50 end of the mRNA facilitates downstream
events that lead to the demise of the mRNA. RppH is functionally analogous
to the eukaryotic Dcp2 decapping enzyme that removes an m7GDP moiety
from the mRNA 50 cap to generate a monophophorylated mRNA that can
subsequently be degraded by the 50 to 30 exoribonuclease Xrn1 (Garneau
et al., 2007). As such, the RppH family of proteins and the Dcp2 decapping
proteins serve similar functions in their respective taxonomic kingdoms. Simi-
larities are also evident in 30 to 50 exonuclease decay where a multisubunit
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Mauldin et al. (2009) use NMR to sho
for function. We discuss their finding
Proteins are nanodevices designed by
molecular evolution. Critically, they are
devices with ‘‘moving parts’’—they
possess internal motions. While no one
doubts the existence of these motions,
defining their relevance to drug design
has been historically difficult. Are they
incidental or essential?
Nuclear magnetic resonance (NMR)
suggests the latter. NMR is unique in its
ability to profile the atomic motions of
bio-macromolecules on multiple time
scales, both comprehensively and nonin-
vasively (Palmer, 2004). As a result, it has
emerged as a premier tool for correlating
protein flexibility with function studies
(flexibility-function studies). NMR shows
clearly that proteins of therapeutic
interest use internal motions for binding,
catalysis, and signal transduction (Cheng
et al., 1994; Nicholson et al., 1995;
Eisenmesser et al., 2002; Boehr et al.,
2006; Namanja et al., 2007). One might
guess then that NMR flexibility-function
studies would be prevalent in pharmaceu-
tical research. Instead, flexibility-function
studies are rather rare events.
Why is this? We suggest some possible
reasons. Because chemical space is
vast and time is short, pharmaceuticalMessing, S.A.J., Gabelli, S.B., Liu, Q., Celesnik, H.,
Belasco, J.G., Pineiro, S.A., and Amzel, L.M.
(2009). Structure 17, this issue, 472–481.
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chet, M.A., Kang, L.W., and Amzel, L.M. (2005).
Arch. Biochem. Biophys. 433, 129–143.
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(2006). Structure 14, 331–343.reakdown:
and Drug Design
niversity of Notre Dame, 251 Nieuwland Scien
w that drug binding can break up co
s in the context of drug discovery i
research is under enormous pressure to
push high-throughput methodologies.
However, NMR dynamics studies involve
recording numerous datasets at higher
signal-to-noise, owing to their quantita-
tive nature. Also, typical drug targets
have higher molecular weights that give
crowded NMR spectra and broad reso-
nances. Together, these factors promote
longer acquisition times and reduced
throughput. Another issue is that the
metrics of protein dynamics—order
parameters, exchange rates, and correla-
tion times—do not translate easily into
strategies for medicinal chemistry. This
contrasts with structural coordinates,
which seemingly lock each atom in place
and thereby dictate where one should
insert, optimize, or remove a ligand func-
tional group. Thus, the dynamics informa-
tion may not be used even if they are
acquired at high-throughput. Together,
the above issues discourage the practice
of flexibility-function studies in pharma-
ceutical research. In turn, this reinforces
old perceptions that protein motions are
small perturbations that can be, to the first
approximation, disregarded, and that
static models are sufficient for efficient
drug discovery.
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In essence, there is a communication
breakdown between the information
available from flexibility-function studies
on the one hand, and the realities of phar-
maceutical research settings on the other.
Should there be concern? The new study
from Mauldin et al. (2009) answers with
a resounding ‘‘yes.’’
Specifically, Mauldin et al. (2009) used
acomprehensivearrayof 15Nand 2H(deute-
rium) NMR spin relaxation experiments to
investigate how the functional motions of
a classic enzyme drug target, dihydrofolate
reductase (DHFR), would respond to the
binding of two well-established DHFR
drugs: the anticancer agent, Methotrexate
(MTX), and the antibiotic Trimethoprim
(TMP). Accordingly, they profiled the
motionsofE.coliDHFRboundwithcofactor
NAPDH (the holoenzyme), in the presence
and absence of MTX and TMP.
For the holoenzyme, Mauldin et al.
(2009) applied backbone 15N relaxation
dispersion experiments and observed
the ms-ms collective motions of loops
surrounding the cofactor and substrate
binding pockets. These motions, previ-
ously identified by Boehr et al. (2006),
reflect the exchange between the
‘‘occluded’’ and ‘‘closed’’ conformers,
9 ª2009 Elsevier Ltd All rights reserved 319
